We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnosing Retinitis Pigmentosa by Determining the Ratio of Dolichol Variants in Plasma or Urine

By LabMedica International staff writers
Posted on 28 Oct 2013
A reliable, high-throughput, and cost-effective liquid chromatography-mass spectrometry technique for the quantitative measurement of dolichols in blood plasma or urine can unambiguously discriminate patients with retinitis pigmentosa from asymptotic carriers of the disease genes, and carriers from normal individuals.

Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degeneration. More...
This disorder is characterized by the progressive loss of photoreceptor cells and may eventually lead to blindness. There are multiple genes that, when mutated, can cause the retinitis pigmentosa phenotype. Among these mutations are the K42E and T206A mutations in the DHDDS (dehydrodolichol diphosphate synthase) gene.

Investigators at the University of Miami (FL, USA) and at Duke University (Durham, NC, USA),using liquid chromatography-mass spectrometry, observed a characteristic shortening of plasma and urinary dolichols in RP patients carrying the K42E and T206A mutations in the DHDDS gene. Dolichol-18 (D18) became the dominant dolichol species in patients compared to dolichol-19 (D19) in normal individuals.

The D18/D19 ratio was calculated and used as an index of dolichol length distribution. K42E/K42E and K42E/T206A patients were found to have significantly higher plasma and urinary D18/D19 ratios than K42E and T206A carriers. The ratios of carriers were significantly higher than normal individuals.

The methodologies and procedures used for dolichol profiling are reliable, high-throughput, and cost-effective. Dolichol profiling, complementary to genotyping, can be readily adapted as a test in the clinic for not only the diagnosis of patients but also identification of carriers with DHDDS or other genetic mutations that may impair dolichol biosynthesis.

"It is our vision that every patient who is affected with an inherited eye disease like RP should have access to a clinician who is knowledgeable about the diseases, as well as to affordable diagnostic testing and counseling," said contributing author Dr. Byron Lam, professor of ophthalmology at the University of Miami. "This diagnostic test is a powerful tool that will help in developing treatments for RP caused by DHDDS mutations."

The study was published in the September 27, 2013, online edition of the Journal of Lipid Research.

Related Links:
University of Miami
Duke University



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.